Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05764239
Other study ID # SYNB1934-CP-003
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date July 5, 2023
Est. completion date March 15, 2024

Study information

Verified date May 2024
Source Synlogic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SYNB1934-CP-003 was designed as a 3-part, adaptive study consisting of a dose-escalating, open-label period (DEP; Part 1) of up to 15 weeks, followed by a 4-week, double-blind, placebo-controlled, randomized withdrawal period (RWP; Part 2), and an open-label extension (OLE; Part 3) of up to 36 months


Description:

In the DEP, all enrolled participants maintained a stable diet reflecting their baseline phenylalanine (Phe) intake and received escalating doses of SYNB1934v1 from approximately 3 to 15 weeks to determine an individually titrated dose (iTD), which was defined as the highest dose the participant was able to tolerate. A participant was defined as having reached an iTD if they tolerated 3 weeks at a dose, regardless of whether other doses were tolerated. Blood Phe level was measured at each dose level after 3 weeks at that level. A responder was defined as a participant who achieved a ≥ 20% reduction in blood Phe level compared to DEP baseline on SYNB1934v1. Participants who completed at least 3 weeks at their iTD during the DEP entered a 4-week RWP in which they were randomized 1:1 to receive SYNB1934v1 at their iTD determined in the DEP or placebo TID. Randomization was stratified on screening Phe level. Participants remained on their assigned dose (iTD of SYNB1934v1 or matching placebo) for the duration of the RWP, unless they developed intolerance or met other discontinuation criteria, and remained on the same diet they consumed during the DEP. Blood Phe level was measured at Weeks 1, 3, and 4 of the RWP. Participants who completed the 4-week RWP may have entered the OLE and received SYNB1934v1 for up to 36 months. During the OLE, participants completed a dose ramp to their iTD over time guided by tolerability. The iTD in the OLE may have been different from the iTD in the DEP. The investigator may have escalated the SYNB1934v1 dose up to 1 × 10^12 live cells based on tolerability. Participants were allowed to modify their standard diet, with guidance from the investigator, if their blood Phe level was < 240 µmol/L.


Recruitment information / eligibility

Status Terminated
Enrollment 35
Est. completion date March 15, 2024
Est. primary completion date March 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Male and female participants were enrolled. Inclusion Criteria: 1. Age = 18 years. 2. Able and willing to voluntarily complete the informed consent process. 3. Diagnosis of phenylketonuria (PKU) and failure to maintain recommended blood Phe levels on existing management (sapropterin, sepiapterin, and/or Phe-restricted diet), demonstrated by uncontrolled blood Phe level > 360 µmol/L on current therapy any time during screening and uncontrolled blood Phe level > 360 µmol/L on current therapy when taking the average of the 3 most recent Phe levels from the participant's medical history (inclusive of any screening values). All screening values must have been obtained more than 7 days apart, as determined by central or local laboratory. 4. Females of childbearing potential must have had a negative pregnancy test at screening and at the end of the DEP (in order to enter the RWP) and RWP (in order to enter the OLE) and been willing to have additional pregnancy tests during the study. 5. Sexually active female participants of childbearing potential must have been willing to use an acceptable method of contraception while participating in the study and for 2 weeks after the last dose. 6. Stable diet including stable medical formula regimen (if used) for at least 1 month prior to screening. 7. If using sapropterin or sepiapterin, must have been on a stable dose for at least 3 months. 8. Willing and able to continue current diet, sapropterin, sepiapterin, and large neutral amino acids unchanged during screening, DEP, and RWP and to engage in all study activities. Exclusion Criteria: 1. Currently taking Palynziq® (pegvaliase-pqpz) (within 1 month of screening). 2. Acute or chronic medical, surgical, psychiatric, or social condition or laboratory abnormality that may have increased participant risk associated with study participation, compromised adherence to study procedures and requirements, and, in the judgment of the investigator, would have made the participant inappropriate for enrollment. 3. A known or suspected diagnosis of DNAJC12 deficiency, biopterin synthesis deficiency, or irritable bowel syndrome. 4. Intolerance to or allergic reaction to Escherichia coli Nissle or any of the ingredients in SYNB1934v1 formulation, or an allergy to cinnamon. Known intolerance to proton pump inhibitors and H2 blockers, since one or the other must have been used. 5. Currently taking or plans to take any type of systemic (e.g., oral or intravenous) antibiotic within 28 days prior to the first dose of SYNB1934v1 through final safety assessment in the RWP, including planned surgery, hospitalizations, dental procedures, or interventional studies that were expected to require antibiotics. Exception: topical antibiotics were allowed. 6. Pregnant, planning to become pregnant, or breastfeeding. 7. Current participation in any other investigational drug study or use of any investigational agent within 30 days or 5 half-lives (whichever was longer) prior to screening. 8. Ever received gene therapy for treatment of PKU.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SYNB1934v1
SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.
Placebo
Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.

Locations

Country Name City State
Canada MAGIC Clinic Calgary Alberta
Canada Hamilton Health Sciences Corporation Hamilton Ontario
Canada Children's Hospital of Eastern Ontario Ottawa Ontario
Canada University Health Network Toronto Ontario
Georgia Medical Genetics and Laboratory Diagnostics Center Tbilisi
Turkey Dokuz Eylül Üniversitesi Arastirma ve Uygulama Hastanesi Balçova Izmir
Turkey Gazi Üniversitesi Hastanesi Yenimahalle Ankara
United States University of Colorado Children's Hospital Aurora Colorado
United States Massachusetts General Hospital, Department of Pediatrics Boston Massachusetts
United States Medical University of South Carolina, Pediatrics Charleston South Carolina
United States Ann & Robert H. Lurie Children's Hospital of Chicago, Pediatrics Chicago Illinois
United States Science 37 Culver City California
United States UT Southwestern Medical Center Dallas Texas
United States University of Florida - Gainesville Gainesville Florida
United States McGovern Medical School/Memorial Hermann Hospital Houston Texas
United States Division of Medical Genetics-Pediatrics, Vanderbilt University Medical Center Nashville Tennessee
United States Children's Hospital Orange County Orange California
United States Stanford University, Department of Pediatrics Palo Alto California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States Oregon Health and Science University Department of Molecular and Medical Genetics Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Synlogic

Countries where clinical trial is conducted

United States,  Canada,  Georgia,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Percent Change From DEP Baseline in Blood Phenylalanine (Phe) Level at Week 3 of iTD During the DEP Baseline for blood Phe level in the DEP was defined as the mean of the duplicate blood Phe level measurements obtained immediately prior to administration of the first dose in the DEP. If only 1 blood Phe level measurement was available, then that measure was used as baseline. The last measurement was the participant's last Week 3 blood Phe level at the iTD of SYNB1934v1. Up to 15 weeks
Secondary Absolute Change From DEP Baseline in Blood Phe Level at Week 3 of iTD During the DEP Baseline for blood Phe level in the DEP was defined as the mean of the duplicate blood Phe level measurements obtained immediately prior to administration of the first dose in the DEP. If only 1 blood Phe level measurement was available, then that measure was used as baseline. The last measurement was the participant's last Week 3 blood Phe level at the iTD of SYNB1934v1. Up to 15 weeks
Secondary Number of Participants With a = 20% Reduction From Baseline in Blood Phe Level at Any Time in the DEP Baseline for blood Phe level in the DEP was defined as the mean of the duplicate blood Phe level measurements obtained immediately prior to administration of the first dose in the DEP. If only 1 blood Phe level measurement was available, then that measure was used as baseline. Blood Phe level was measured at each dose level after 3 weeks at that level. Up to 15 weeks
See also
  Status Clinical Trial Phase
Completed NCT05099640 - A Study of PTC923 in Participants With Phenylketonuria Phase 3
Completed NCT01924026 - Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study N/A
Completed NCT01428258 - Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria N/A
Completed NCT00925054 - Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU Phase 2
Completed NCT00778206 - PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
Recruiting NCT05948020 - Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria N/A
Recruiting NCT05781399 - First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria Phase 1
Completed NCT02555579 - Simplified Diet Approach in Phenylketonuria N/A
Completed NCT03097250 - MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria
Completed NCT01965912 - Kuvan®'s Effect on the Cognition of Children With Phenylketonuria Phase 4
Completed NCT01965691 - Protein Requirements in Children With Phenylketonuria (PKU) N/A
Completed NCT00789568 - A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects Phase 1
Completed NCT00688844 - Nutritional and Neurotransmitter Changes in PKU Subjects on BH4 N/A
Terminated NCT01465100 - Liver Cell Transplant for Phenylketonuria Phase 1/Phase 2
Completed NCT01732471 - Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria Phase 3
Completed NCT04879277 - Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria N/A
Completed NCT02176603 - Observational Study of Endothelial Dysfunction in Phenylketonuria N/A
Completed NCT01819727 - An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165 Phase 3
Terminated NCT01904708 - Moderate Intensity Exercise and Phenylketonuria N/A
Completed NCT01869972 - Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia N/A